Author

P. J. Goodwin

Observed name: P.J. Goodwin

Institutions: Mount Sinai Hospital, University of Toronto, Lunenfeld-Tanenbaum Research Institute

Observed institutions: Mount Sinai Hospital, University of Toronto, Lunenfeld-Tanenbaum Research Institute

OpenAlex ID: A5126176486

Abstract PS4-08-11: Standardized Definitions for Efficacy End Points (STEEP, STEEP2) in the CCTG MA.32 randomized breast cancer trial of metformin versus placebo: Implications of the type of recurrence and new non-breast cancer primary on outcome assessment

2026 · K. J. Jerzak, W. R. Parulekar, et al. · Clinical Cancer Research

Abstract PS3-01-30: Change in mammographic density (MD) with metformin use: Alliance A211201, A companion study to NCIC study MA.32

2026 · M. Wood, M. I. Elsaid, et al. · Clinical Cancer Research

Abstract PS4-09-29: Variation in weight loss and intervention engagement in the Breast Cancer Weight Loss (BWEL) trial by language and ethnicity (Alliance)

2026 · A. Odai-Afotey, K. V. Ballman, et al. · Clinical Cancer Research

Abstract PS2-08-29: Plasma hepcidin as a prognostic biomarker in obese and non-obese patients with early breast cancer (BC): a pooled analysis of two prospective cohort studies

2026 · E. A. Cescon, P. J. Goodwin, et al. · Clinical Cancer Research

The Impact of Disease Progression on Health-Related Quality of Life Outcomes in Patients with Oligo-Metastatic Disease at 12-Months post Stereotactic Body Radiotherapy

2022 · A.S. Barry, A. Bezjak, et al. · International Journal of Radiation Oncology*Biology*Physics

Works count: 5

Citation count:

H-index:

I10-index: